Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2022 Filed Mar 31, 2022 22:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $45.46 | $113,647.50 |
DisclosureSEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 100,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $45.140 to $45.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,852 | $44.81 | $172,596.56 |
DisclosureSEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 189,104 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.340 to $45.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $36.40 | $91,000.00 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 102,562 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F12 · price: This transaction was executed in multiple trades at prices ranging from $36.350 to $36.470, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $36.29 | $90,730.00 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 102,537 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F11 · price: This transaction was executed in multiple trades at prices ranging from $36.160 to $36.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 353 | $37.57 | $13,262.21 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 192,956 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $37.510 to $37.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,499 | $36.78 | $128,679.22 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 193,309 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $36.470 to $37.420, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $38.04 | $95,107.50 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 105,062 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $37.500 to $38.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $37.10 | $92,752.50 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 105,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $36.840 to $37.500, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,517 | $39.74 | $60,285.58 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 196,808 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $39.335 to $40.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 21:15 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,335 | $38.58 | $90,074.96 |
DisclosureSEC source: 0001447362-22-000048 · wf-form4_164746529057335.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 198,325 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.250 to $39.180, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $39.71 | $99,262.50 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 107,562 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $39.375 to $40.020, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $39.18 | $97,960.00 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 107,537 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $39.050 to $39.370, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,852 | $38.97 | $150,127.85 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 200,660 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $38.885 to $39.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $39.50 | $98,757.50 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 110,062 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $39.180 to $39.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $39.09 | $97,735.00 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 110,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $39.000 to $39.180, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:20 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,852 | $38.65 | $148,875.95 |
DisclosureSEC source: 0001447362-22-000028 · wf-form4_164573761313510.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 204,512 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.170 to $39.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $46.52 | $116,295.00 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 112,562 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F11 · price: This transaction was executed in multiple trades at prices ranging from $46.190 to $46.925, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $45.88 | $114,710.00 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 112,537 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $45.210 to $46.190, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 468 | $45.13 | $21,122.24 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 208,364 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $45.070 to $45.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,384 | $44.42 | $150,324.05 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 208,832 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $44.010 to $45.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $46.64 | $116,587.50 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 115,062 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $46.370 to $46.870, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,500 | $46.73 | $116,825.00 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 115,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.500 to $47.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:58 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,852 | $46.33 | $178,443.90 |
DisclosureSEC source: 0001447362-22-000026 · wf-form4_164462030150237.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 212,216 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.850 to $46.830, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:38 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,915 | $35.50 | $138,982.50 |
DisclosureSEC source: 0001447362-22-000024 · wf-form4_164323308734113.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 117,562 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $35.36 to $35.60, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:38 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,914 | $35.44 | $138,712.16 |
DisclosureSEC source: 0001447362-22-000024 · wf-form4_164323308734113.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 117,537 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.36 to $35.48, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:38 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 6,802 | $35.37 | $240,586.74 |
DisclosureSEC source: 0001447362-22-000024 · wf-form4_164323308734113.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 216,068 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.04 to $35.66, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 22:34 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,174 | $35.29 | $147,300.46 |
DisclosureSEC source: 0001447362-22-000022 · wf-form4_164306363418301.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 121,477 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $35.25 to $35.33, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 22:34 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,175 | $35.47 | $148,087.25 |
DisclosureSEC source: 0001447362-22-000022 · wf-form4_164306363418301.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 121,451 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.33 to $35.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 22:34 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 7,255 | $35.13 | $254,868.15 |
DisclosureSEC source: 0001447362-22-000022 · wf-form4_164306363418301.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 222,870 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:19 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 661 | $35.18 | $23,253.98 |
DisclosureSEC source: 0001447362-22-000020 · wf-form4_164271713461959.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 125,651 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $35.11 to $35.24, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:19 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 661 | $35.07 | $23,181.27 |
DisclosureSEC source: 0001447362-22-000020 · wf-form4_164271713461959.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 125,626 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.11, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:19 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,148 | $35.51 | $40,765.48 |
DisclosureSEC source: 0001447362-22-000020 · wf-form4_164271713461959.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 230,125 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.24 to $35.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 10, 2022 Filed Jan 20, 2022 22:16 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
GiftCommon Stock | 122,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000018 · wf-form4_164271698171877.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 0 F1 · balance_after: On January 5, 2022, the Reporting Person transferred 5,547 shares of Castle Biosciences, Inc. common stock to his direct holdings. F2 · balance_after: On January 10, 2022, the Reporting Person transferred 122,181 shares collectively of Castle Biosciences, Inc. common stock to The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, and The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, all of which the Reporting Person is the trustee and his children are the beneficiaries. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,898 | $42.09 | $79,894.41 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 126,312 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F13 · price: This transaction was executed in multiple trades at prices ranging from $41.820 to $42.470, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,477 | $41.04 | $101,646.17 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 128,210 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F12 · price: This transaction was executed in multiple trades at prices ranging from $40.670 to $41.660, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,375 | $40.44 | $176,916.25 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 126,287 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F11 · price: This transaction was executed in multiple trades at prices ranging from $40.280 to $40.670, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,840 | $43.64 | $211,207.92 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 231,273 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $43.470 to $44.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,763 | $43.21 | $119,391.99 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 236,113 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $42.470 to $43.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,618 | $43.50 | $200,869.15 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 130,687 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $43.305 to $43.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,618 | $43.04 | $198,735.63 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 130,662 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $42.695 to $43.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 300 | $45.04 | $13,511.10 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 238,876 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $44.910 to $45.160, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:56 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 6,817 | $43.93 | $299,491.26 |
DisclosureSEC source: 0001447362-22-000007 · wf-form4_164151336019192.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 239,176 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.770 to $44.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 04, 2022 Filed Jun 13, 2022 23:00 UTC Amendment |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,375 | $43.46 | $190,124.38 |
DisclosureSEC source: 0001447362-22-000111 · wf-form4a_165516119425693.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 130,930 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $43.300 to $43.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 04, 2022 Filed Jun 13, 2022 23:00 UTC Amendment |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,375 | $43.02 | $188,216.88 |
DisclosureSEC source: 0001447362-22-000111 · wf-form4a_165516119425693.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 130,905 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $42.695 to $43.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 04, 2022 Filed Jun 13, 2022 23:00 UTC Amendment |
BRADBURY DANIELDirector
|
SaleCommon Stock | 7,303 | $43.92 | $320,762.37 |
DisclosureSEC source: 0001447362-22-000111 · wf-form4a_165516119425693.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 238,690 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.750 to $44.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:01 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000272 · wf-form4_163953007296482.xml · derivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021. F5 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:01 UTC |
Stokes FrankChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 24,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000272 · wf-form4_163953007296482.xml · derivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,679 Underlying: Common Stock · 24,679 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on December 10, 2022. F4 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on December 10, 2022. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:01 UTC |
Stokes FrankChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 42,550 | $0.00 Strike: $40.52 | $0.00 |
DisclosureSEC source: 0001447362-21-000272 · wf-form4_163953007296482.xml · derivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,550 Underlying: Common Stock · 42,550 shares Expires 2031-12-09 F3 · derivative.exercise_date: 25% of the shares shall vest on December 10, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:01 UTC |
Stokes FrankChief Financial Officer
|
Tax withholdingCommon Stock | 895 | $40.52 | $36,265.40 |
DisclosureSEC source: 0001447362-21-000272 · wf-form4_163953007296482.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,330 Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:01 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-21-000272 · wf-form4_163953007296482.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 305 shares acquired on August 31, 2021, under the Issuer's employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.